INKT vs. SRZN, NKGN, TARA, INAB, CRTX, ESLA, ACHL, SABS, PLUR, and DYAI
Should you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Surrozen (SRZN), NKGen Biotech (NKGN), Protara Therapeutics (TARA), IN8bio (INAB), Cortexyme (CRTX), Estrella Immunopharma (ESLA), Achilles Therapeutics (ACHL), SAB Biotherapeutics (SABS), Pluri (PLUR), and Dyadic International (DYAI). These companies are all part of the "medical" sector.
Surrozen (NASDAQ:SRZN) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, community ranking, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.
66.6% of Surrozen shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 43.5% of Surrozen shares are held by insiders. Comparatively, 17.8% of MiNK Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Surrozen has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500.
MiNK Therapeutics has a consensus target price of $9.00, indicating a potential upside of 877.62%. Given Surrozen's higher probable upside, analysts clearly believe MiNK Therapeutics is more favorable than Surrozen.
In the previous week, MiNK Therapeutics had 1 more articles in the media than Surrozen. MarketBeat recorded 1 mentions for MiNK Therapeutics and 0 mentions for Surrozen. MiNK Therapeutics' average media sentiment score of 0.00 equaled Surrozen'saverage media sentiment score.
MiNK Therapeutics has lower revenue, but higher earnings than Surrozen. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.
Surrozen's return on equity of 0.00% beat MiNK Therapeutics' return on equity.
MiNK Therapeutics received 7 more outperform votes than Surrozen when rated by MarketBeat users. Likewise, 66.67% of users gave MiNK Therapeutics an outperform vote while only 16.67% of users gave Surrozen an outperform vote.
Summary
MiNK Therapeutics beats Surrozen on 8 of the 14 factors compared between the two stocks.
Get MiNK Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MiNK Therapeutics Competitors List
Related Companies and Tools
